Clinical Trial Update: Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial from University College London evaluating CD19-directed CAR T-cell therapy for relapsed/refractory Primary CNS Lymphoma; the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cns Lymphoma

Drugs mentioned

• Investigational CD19-directed CAR T-cell therapy (CD19-directed CAR T-cell therapy)

Snippet

Sponsor: University College, London | Conditions: Primary CNS Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING